Table 2.
Affected Organs and Conditions 2 | Observed Effects | Dose and Duration | References |
---|---|---|---|
Beneficial effects | |||
Joints | Reduced itching in uremic patients | 550 mg twice a day (4 weeks) |
[38] |
pancreatic β-cell | β-cell function preserved and improved | 25 mg/kg daily intake (4 weeks) |
[18,39] |
Reduced the rate of diabetes incidence | 500 mg twice per day (2.5 years) |
[19] | |
No effect on the incidence of being diabetes-free | 1200 mg daily intake (5 years) |
[20] | |
Ineffective in prevention or delaying clinical onset of diabetes | 1.2 g daily intake (3 years) |
[21] | |
Skin | Reduced acne lesions and severity | 4% gel applied twice daily (8 weeks) |
[26] |
Attenuated immunosuppression with alterations in metabolism and apoptosis | 5% lotion applied before UV exposure | [40] | |
Psychology | Improvements against depression | 0.5–1.5 g daily intake (3 weeks) |
[22] |
Relief from anxiety | A dose of 2 ug 3 h prior to test |
[23] | |
Kidney | Lowered serum concentrations of phosphorus, parathyroid hormone, and LDL, and increased serum HDL | 500 mg/day (with and increment every 2 weeks) (12 weeks) |
[41] |
Skin cancers non-melanoma | Reduced incidence of various types of skin cancers and actinic keratoses | 500 mg twice daily (4 months) |
[42] |
Adverse Effects | |||
Minor effects | Frontal dull headaches, nausea, headache, dizziness | 1–18 g immediate |
[43,44] |
Pancreatic β-cell/plasma | Decreased insulin sensitivity, increased oxidative stress (H2O2) | 2 g daily (2 weeks) |
[45,46] |
Liver | Parenchymal-cell injury, portal fibrosis and cholestasis, liver injury | 3, 9 g daily (10 days) |
[47] |
Lymphocytes, platelets | Uremic toxicity-related cancer and thrombocytopenia | 1300, 1500 mg daily (24 weeks) |
[48] |
Kidney/platelets | Decreased serum phosphorus and thrombocytopenia | 0.52–2 g daily (3–6 months) |
[49,50] |
1 Some examples of human studies are presented. For more information on the beneficiary effects, check Reference [27]. 2 In all human applications except for skin, NAM was administered through dietary intake.